Announcements Trials
Browse Landscape

Phase

Phase 2 223Phase 1/2 109Phase 1 102Phase 3 91Phase 2/3 17Phase EARLY_PHASE1 6Phase NA 4Phase 4 3

Status

Recruiting 3Completed 3Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1CNS 1

Conditions

Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Glioblastoma 1

Interventions

Propofol 9Sevoflurane 7Rituximab 7Specimen Handling 6Magnetic Resonance Spectroscopy 6Dexamethasone 6Trastuzumab 5Enoxaparin 5Bevacizumab 5Nivolumab 4Carboplatin 4Capecitabine 4Bupivacaine 4trametinib 3pirtobrutinib 3pembrolizumab 3dabrafenib 3atezolizumab 3apixaban 3Lenalidomide 3Indocyanine Green 3Gemcitabine 3Docetaxel 3Cyclophosphamide 3zanubrutinib 2venetoclax 2trastuzumab deruxtecan 2ribociclib 2polyethylene glycol 3350 2pertuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Recruiting × pembrolizumab × Clear all
NCT06031233 2026-03-30

MINUTE

Isala

Phase 4 Recruiting
776 enrolled
Tumor-Agnostic

Neoplasms

NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Mayo Clinic

Phase 4 Recruiting
75 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT05235737 2023-08-31

PIRG

Medical University of Silesia

Phase 4 Recruiting
36 enrolled
CNS

Parkinson Disease 4, Autosomal Dominant Lewy Body, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡